Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Written by Thomas Niel for The Motley Fool -> Boston Scientific's shares have fallen over 50% year to date as the medtech company continues to walk back full-year 2026 guidance. Sell-side analysts …
Boston Scientific's shares have fallen over 50% year to date as the medtech company continues to walk back full-year 2026 guidance. Boston Scientific
Read Full Story at Nasdaq News →Why This Matters
The medtech sector’s long-term growth potential remains intact despite near-term volatility, making stocks like Boston Scientific a high-stakes bet for investors betting on innovation in healthcare. A 65% upside projection signals confidence in the company’s ability to navigate regulatory hurdles and capitalize on an aging global population’s demand for advanced medical devices. This optimism contrasts sharply with the stock’s steep decline, raising questions about whether the market is overreacting to short-term setbacks.
Background Context
Boston Scientific has spent years positioning itself as a leader in minimally invasive therapies, particularly in cardiology and urology, but its recent guidance withdrawal reflects broader challenges in medtech, including supply chain pressures and post-pandemic demand normalization. The company’s struggles mirror those of peers like Medtronic and Abbott Laboratories, which have also faced investor scrutiny over growth strategies. Meanwhile, the FDA’s evolving scrutiny of device approvals has added another layer of uncertainty for the industry.
What Happens Next
Analysts’ bullish outlook hinges on Boston Scientific’s ability to stabilize its core businesses and accelerate pipeline execution, with key product launches expected to drive revenue by mid-2025. Investors will closely watch the company’s Q4 earnings and any updates to its 2026 targets, as a failure to regain confidence could trigger further sell-offs. The stock’s valuation—now trading at a discount relative to its historical multiples—may attract activist investors or acquisitive rivals looking to exploit the dip.
Bigger Picture
Medtech’s resilience in the face of macroeconomic headwinds underscores its defensive appeal, especially as healthcare spending continues to rise amid chronic disease proliferation. The sector’s M&A activity is poised to intensify, with cash-rich companies seeking to fill gaps in innovation pipelines—a trend that could reshape competitive dynamics. Meanwhile, regulatory reforms and reimbursement pressures remain wild cards that could either accelerate or derail the industry’s long-term trajectory.
